Atomwise is a TechBio company leveraging AI/ML to revolutionize small molecule drug discovery. The Atomwise team invented the use of deep learning for structure-based drug design; a core technology of Atomwise's best-in-class AI discovery and optimization engine, which is differentiated by its ability to find and optimize novel chemical matter. The company's belief is that structurally novel chemical matter increases the likelihood of developing first-in-class and best-in-class medicines that have the potential to transform patient care. Atomwise has extensively tested its discovery and optimization engine, delivering hit ID success in over 230 academic and collaboration projects-to-date that cover a wide breadth of protein classes and numerous “hard-to-drug” targets. Atomwise is building a pipeline of small-molecule drug candidates with first-in-class and best-in-class potential in immunology.